S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Tech insider: "Watch your mailbox" (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Tech insider: "Watch your mailbox" (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Tech insider: "Watch your mailbox" (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Tech insider: "Watch your mailbox" (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:CCCC

C4 Therapeutics (CCCC) Stock Price, News & Analysis

$8.99
+0.19 (+2.16%)
(As of 02/23/2024 ET)
Today's Range
$8.55
$9.66
50-Day Range
$4.35
$8.99
52-Week Range
$1.06
$9.66
Volume
4.39 million shs
Average Volume
5.21 million shs
Market Capitalization
$443.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.88

C4 Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
9.8% Upside
$9.88 Price Target
Short Interest
Healthy
8.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.05mentions of C4 Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.60) to ($2.38) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.56 out of 5 stars

Medical Sector

871st out of 941 stocks

Biological Products, Except Diagnostic Industry

146th out of 158 stocks


CCCC stock logo

About C4 Therapeutics Stock (NASDAQ:CCCC)

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CCCC Stock Price History

CCCC Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
C4 Therapeutics price target raised by $1 at Stifel, here's why
C4 Therapeutics Stock (NASDAQ:CCCC) Insider Trades
Biden fires warning shot for retirees...
Biden’s not holding back...He’s warned you that he plans to raise: Income taxes, death taxes, capital gains taxes & corporate taxes.Some or all of which WILL affect you or your family in one way or another…But it’s not too late… yet. Thousands of Americans are getting their FREE WEALTH PROTECTION KIT to discover the secret to protecting your retirement savings from Biden and inflation...
CCCC Feb 2024 9.000 put
CCCC Feb 2024 4.500 put
Analyst Expectations For C4 Therapeutics's Future
C4 Therapeutics Inc (CCCC)
SRPT Aug 2024 140.000 call
C4 Therapeutics cuts 30% of its workforce
See More Headlines
Receive CCCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/23/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CCCC
Fax
N/A
Employees
146
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.89
High Stock Price Target
$20.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+8.8%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-128,180,000.00
Net Margins
-663.05%
Pretax Margin
-658.12%

Debt

Sales & Book Value

Annual Sales
$31.10 million
Book Value
$5.91 per share

Miscellaneous

Free Float
45,353,000
Market Cap
$443.03 million
Optionable
Optionable
Beta
2.99
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Andrew J. Hirsch M.B.A. (Age 53)
    CEO, President & Director
    Comp: $971k
  • Dr. Kenneth C. Anderson M.D. (Age 73)
    Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board
    Comp: $39.03k
  • Dr. Stewart  FisherDr. Stewart Fisher (Age 57)
    Chief Scientific Officer
    Comp: $657.34k
  • Mr. Scott N. Boyle M.B.A. (Age 46)
    Ph.D., Chief Business Officer
    Comp: $672.78k
  • Dr. Nathanael S. Gray Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Kendra Adams
    Chief Financial Officer
  • Mr. Mark Mossler (Age 51)
    Chief Accounting Officer
  • Ms. Jolie M. Siegel J.D. (Age 47)
    Chief Legal Officer & Corporate Secretary
    Comp: $610.4k
  • Ms. Kelly A. Schick (Age 44)
    Chief People Officer
  • Dr. Isabel Chiu Ph.D.
    Senior Vice President of Strategic Alliances & Business Development














CCCC Stock Analysis - Frequently Asked Questions

Should I buy or sell C4 Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CCCC shares.
View CCCC analyst ratings
or view top-rated stocks.

What is C4 Therapeutics' stock price target for 2024?

6 analysts have issued 1 year price targets for C4 Therapeutics' shares. Their CCCC share price targets range from $2.00 to $20.00. On average, they expect the company's stock price to reach $9.88 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price.
View analysts price targets for CCCC
or view top-rated stocks among Wall Street analysts.

How have CCCC shares performed in 2024?

C4 Therapeutics' stock was trading at $5.65 at the start of the year. Since then, CCCC stock has increased by 59.1% and is now trading at $8.99.
View the best growth stocks for 2024 here
.

Are investors shorting C4 Therapeutics?

C4 Therapeutics saw a decline in short interest in January. As of January 31st, there was short interest totaling 3,350,000 shares, a decline of 39.6% from the January 15th total of 5,550,000 shares. Based on an average daily volume of 14,290,000 shares, the short-interest ratio is currently 0.2 days. Currently, 8.7% of the company's shares are short sold.
View C4 Therapeutics' Short Interest
.

When is C4 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CCCC earnings forecast
.

How were C4 Therapeutics' earnings last quarter?

C4 Therapeutics, Inc. (NASDAQ:CCCC) posted its earnings results on Wednesday, November, 10th. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.06. The company had revenue of $8.50 million for the quarter, compared to the consensus estimate of $7.28 million. C4 Therapeutics had a negative net margin of 663.05% and a negative trailing twelve-month return on equity of 53.89%.

When did C4 Therapeutics IPO?

(CCCC) raised $150 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

Who are C4 Therapeutics' major shareholders?

C4 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (14.49%), Commodore Capital LP (7.71%), Price T Rowe Associates Inc. MD (5.19%), Price T Rowe Associates Inc. MD (5.19%), Vanguard Group Inc. (4.06%) and Point72 Asset Management L.P. (3.98%). Insiders that own company stock include Adam Crystal, Andrew Hirsch, Elena Prokupets, Jolie Siegel, Malcolm Salter, Stewart Fisher and Utpal Koppikar.
View institutional ownership trends
.

How do I buy shares of C4 Therapeutics?

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CCCC) was last updated on 2/24/2024 by MarketBeat.com Staff